Dr. Janet Scott is a Clinical Lecturer in Infectious Disease at the MRC-University of Glasgow Centre for Virus Research. Her research interests are in optimising the doses of anti-viral therapeutics using pharmacokinetic and pharmacodynamic in vitro and in silico models, with a focus for Lassa and Ebola viruses, and characterising Post Ebola Syndrome.
She trained in Parasitology at the University of Glasgow and holds a PhD in the cellular immuno-epidemiology of Schistosomiasis also from the University of Glasgow, with research in The Gambia, Zimbabwe and Senegal. After a degree in Medicine at the University of Oxford she joined the TB Vaccine team as a clinical academic in parallel with her clinical training.
During the Ebola 2014–16 epidemic she was the clinical lead for the Brincidofovir Trial (Monrovia, Liberia), and Convalescent Plasma (Freetown, Sierra Leone) and was also in the clinical trial team for the Tekmira trial. She lead a collaborative team Characterising post Ebola syndrome, in Freetown, which both provided clinical care and developed data collection tools and conducted observational and clinical research into Post Ebola Syndrome. She is now engaged in the pharmacokinetic/pharmacodynamics analysis of data gathered during the Ebola drug trials and Ebola survivor clinics, and developing methods for dose optimising drugs for category 4 viruses.